Synapsoft logo
AI Insights from Disclosures
Searching...
ILYANG PHARMACEUTICAL CO.,LTD 007570
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
ILYANG PHARMACEUTICAL CO.,LTD discloses its financial statements on a consolidated basis, including ILYANG PHARMACEUTICAL CO.,LTD and its Chinese subsidiaries Yangzhou Ilyang Pharmaceutical Co., Ltd., Ilyang Biopharm Co., Ltd., and Kantech Co., Ltd. For the first half of its 54th fiscal year, the company recorded, on a consolidated basis, revenue of KRW 161.2 billion, operating profit of KRW 5.5 billion, and net income of KRW 4.5 billion, and on a standalone basis, revenue of KRW 113.6 billion, operating profit of KRW 2.3 billion, and net income of KRW 2.4 billion.
Representative Director Jung Yuseok
Founded July 1, 1946
Corporation Type KOSPI
Industry Classification Manufacture of medicaments
Corporate number 11011-0124802
Business number 209-81-00872
Phone Number 02-570-3700
Fax Number 02-570-3700
Company Address 110 Hagal-ro, Giheung-gu, Yongin-si, Gyeonggi-do
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant